 From efficacy to safety, uncertainty to interchangeability, we explore eight issues regarding the awareness of biosimilar medications. With the recent US Food and Drug Administration (FDA) approval of a fourth biosimilar medication, these compounds remain a hot topic in many areas of medicine, including nephrology,[1] oncology, endocrinology, gastroenterology, and rheumatology, as attested by the several biosimilar trials presented at the recent American College of Rheumatology Annual Meeting.
www.medscape.com/viewarticle/872115?src=WNL_infoc_161127_MSCPEDIT_TEMP2&uac=151849FY&impID=1240771&faf=1 |
News ArticlesNews that has been personally selected by the Editorial team. Archives
March 2019
Categories |
RSS Feed